PSP Tau Caspase Cleavage and Truncation

PSP Tau Caspase Cleavage and Truncation

Overview

Caspase-mediated cleavage of tau protein represents a critical pathological modification in Progressive Supranuclear Palsy (PSP) that promotes tau aggregation, enhances neurotoxicity, and generates truncated tau fragments with distinct seeding properties. Caspase cleavage removes regulatory domains, exposes hydrophobic regions, and produces aggregation-prone fragments that serve as seeds for filament formation. This mechanism represents a key link between apoptotic signaling and tau pathology in 4R-tauopathies.

Caspase Family Overview

Key Caspases in Tau Pathology

| Caspase | Type | Primary Target in Tau | PSP Relevance |
|---------|------|----------------------|----------------|
| Caspase-3 | Executioner | Asp421, Asp393 | High |
| Caspase-6 | Executioner | Asp13, His404 | Moderate |
| Caspase-7 | Executioner | Asp421 | Moderate |
| Caspase-8 | Initiator | Extracellular tau | High |
| Caspase-9 | Initiator | Mitochondrial pathway | Moderate |

Activation Pathways

Caspases in PSP can be activated through multiple pathways:

Intrinsic (mitochondrial) pathway: Cytochrome c release triggers apoptosome formation, activating caspase-9 and downstream executioner caspases

Extrinsic pathway: Death receptor engagement activates caspase-8

ER stress pathway: Caspase-4/12 activation (in rodents) or caspase-4 in human astrocytes

Inflammasome-mediated: Caspase-1 activation through NLRP3 inflammasome can cross-talk to executioner caspases

Tau Cleavage Sites

...

PSP Tau Caspase Cleavage and Truncation

Overview

Caspase-mediated cleavage of tau protein represents a critical pathological modification in Progressive Supranuclear Palsy (PSP) that promotes tau aggregation, enhances neurotoxicity, and generates truncated tau fragments with distinct seeding properties. Caspase cleavage removes regulatory domains, exposes hydrophobic regions, and produces aggregation-prone fragments that serve as seeds for filament formation. This mechanism represents a key link between apoptotic signaling and tau pathology in 4R-tauopathies.

Caspase Family Overview

Key Caspases in Tau Pathology

| Caspase | Type | Primary Target in Tau | PSP Relevance |
|---------|------|----------------------|----------------|
| Caspase-3 | Executioner | Asp421, Asp393 | High |
| Caspase-6 | Executioner | Asp13, His404 | Moderate |
| Caspase-7 | Executioner | Asp421 | Moderate |
| Caspase-8 | Initiator | Extracellular tau | High |
| Caspase-9 | Initiator | Mitochondrial pathway | Moderate |

Activation Pathways

Caspases in PSP can be activated through multiple pathways:

Intrinsic (mitochondrial) pathway: Cytochrome c release triggers apoptosome formation, activating caspase-9 and downstream executioner caspases

Extrinsic pathway: Death receptor engagement activates caspase-8

ER stress pathway: Caspase-4/12 activation (in rodents) or caspase-4 in human astrocytes

Inflammasome-mediated: Caspase-1 activation through NLRP3 inflammasome can cross-talk to executioner caspases

Tau Cleavage Sites

Major Caspase Cleavage Sites

Tau Protein (441 aa)
├── Caspase-3/7: Asp421 ──────────────────────┐
├── Caspase-3: Asp393 ─────────────────────────┤
├── Caspase-6: Asp13 ────────┐ │
├── Caspase-6: His404 ───────┤ │
└── Truncation Products ─────┴─────────────────┘

Key Truncation Products

TauΔC421 (Tau 1-421)

• Generated by: Caspase-3 and caspase-7
• Significance: Most studied truncation product in PSP
• Properties:
• Severely impaired microtubule binding
• Enhanced aggregation propensity
• Forms stable oligomers
• Transcellular propagation capacity
• Found in PSP brain tissue at elevated levels

TauΔC393 (Tau 1-393)

• Generated by: Caspase-3
• Significance: Generates tau fragment containing both N-terminal projection domain and microtubule-binding repeats
• Properties:
• Accelerated filament formation
• Reduced solubility
• Interaction with full-length tau to co-aggregate

TauN-terminus (1-13)

• Generated by: Caspase-6 cleavage at Asp13
• Significance: Produces highly aggregation-prone fragment
• Properties:
• Seeds tau aggregation efficiently
• Found in PSP neurons and glia
• Correlates with disease severity

Molecular Mechanisms

Cleavage-Induced Conformational Changes

Caspase cleavage at Asp421 removes the C-terminal tail, which normally acts as a "chaperone" keeping tau in a soluble, microtubule-bound state. This removal leads to:

Loss of negative charge: C-terminal region contains acidic residues that maintain solubility

Exposure of hydrophobic residues: microtubule-binding repeats become more accessible

Enhanced β-sheet formation: truncation promotes conformational transition to β-sheet rich state

Reduced tau-tau repulsion: removes steric hindrance between tau molecules

Seeding and Propagation

Truncated tau fragments serve as superior seeds compared to full-length tau:

| Property | Full-Length Tau | Caspase-Truncated Tau |
|----------|-----------------|----------------------|
| Aggregation lag time | 48-72 hours | 4-8 hours |
| Seed efficiency | Baseline | 5-10x higher |
| Filament morphology | Variable | More uniform |
| Cell-to-cell transfer | Moderate | Enhanced |

Interaction with Phosphorylation

Caspase cleavage and phosphorylation synergistically promote pathology:

• Phosphorylation before cleavage: Phosphorylated tau is more susceptible to caspase cleavage
• Cleavage before phosphorylation: Truncated tau is phosphorylated more efficiently by GSK-3β and CDK5
• Feedback loop: Cleavage products activate kinases that further promote phosphorylation and additional cleavage

Regional Patterns in PSP

Brain Region Distribution

Caspase-cleaved tau (detected by anti-tauC3 antibodies) shows distinct regional patterns in PSP:

• Globus pallidus internus: High density of tauC3+ neurons and terminals
• Substantia nigra: Prominent in remaining neurons (especially pars reticulata)
• Brainstem nuclei: Red nucleus, oculomotor nucleus, pontine nuclei
• Cerebellar dentate nucleus: Moderate levels
• Frontal cortex: Layer 3 pyramidal neurons

Cell-Type Specificity

• Neurons: Primary source of caspase-cleaved tau; correlates with NFT burden
• Oligodendrocytes: Coiled bodies show caspase cleavage in PSP
• Astrocytes: Tau-positive astrocytes in PSP show caspase activation

Biomarker Potential

CSF Biomarkers

Caspase-generated tau fragments can be detected in cerebrospinal fluid:

• TauC3 in CSF: Elevated in PSP vs. healthy controls
• Fragments: 20-25 kDa fragments corresponding to cleavage products
• Diagnostic utility: AUROC 0.72-0.78 for PSP vs. PD differentiation

Blood Biomarkers

• Plasma tauC3: Technical challenges due to low abundance
• Extracellular vesicle tau: Truncated tau in neuron-derived EVs shows promise

Imaging Correlates

• Tau PET: Caspase-cleaved tau shows different binding patterns than total tau
• PET ligands: Novel tracers under development that preferentially bind truncated tau

Therapeutic Implications

Caspase Inhibitors

| Agent | Target | Stage | Notes |
|-------|--------|-------|-------|
| Z-DEVD-FMK | Caspase-3/7 | Preclinical | Poor brain penetration |
| VX-765 | Caspase-1 | Phase 2 | Cross-talk to caspase-3 |
| Emricasan | Pan-caspase | Preclinical | Broad spectrum |
| Ac-DEVD-CHO | Caspase-3 | Research | Peptidic |

Indirect Strategies

• Anti-apoptotic modulation: Bcl-2 family inhibitors
• Neurotrophic factors: Promote survival signaling to reduce caspase activation
• Inflammasome inhibition: NLRP3 inhibitors reduce caspase-1 mediated cross-activation

Tau-Directed Approaches

• Cleavage-resistant tau: Genetic approaches to mutate cleavage sites
• Antibodies against truncated tau: Passive immunization strategies
• Aggregation inhibitors: Target the enhanced aggregation propensity of fragments

Interaction with Other PSP Mechanisms

With Apoptosis

Caspase cleavage of tau is both cause and consequence of apoptotic cell death:

• Initial caspase activation can occur independently of tau cleavage
• Once generated, truncated tau can induce further caspase activation
• Creates self-perpetuating cycle of tau pathology and cell death

With Neuroinflammation

• Inflammasome activation leads to caspase-1 activation
• Caspase-1 can activate executioner caspases
• Microglial release of inflammatory caspases affects extracellular tau

With Mitochondrial Dysfunction

• Mitochondrial permeability transition releases cytochrome c
• Triggers apoptosome and caspase-9 activation
• Links mitochondrial dysfunction to tau cleavage

Research Directions

Emerging Questions

Temporal sequence: Does caspase cleavage initiate or propagate tau pathology?

Cell-to-cell spread: How do truncated tau fragments transfer between cells?

Strain specificity: Do different truncation products form distinct tau strains?

Therapeutic targeting: Can cleavage site blockade prevent pathology?

Preclinical Models

• Transgenic models: TauΔC421 knock-in mice show enhanced pathology
• Viral vectors: AAV-mediated tauC421 expression in rodents
• iPSC models: Neurons from PSP patients show elevated caspase activation

References

[Rohn et al., Caspase cleavage of tau in Alzheimer's disease brain (2002)](https://pubmed.ncbi.nlm.nih.gov/11854286/)

[Gamblin et al., Caspase-3 cleavage of tau is an early event in Alzheimer disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12736939/)

[Yuan et al., Caspase cleavage of tau in progressive supranuclear palsy (2006)](https://pubmed.ncbi.nlm.nih.gov/17046758/)

[Dolan et al., Tau cleavage by caspases in progressive supranuclear palsy (2010)](https://pubmed.ncbi.nlm.nih.gov/20869590/)

[Basurto-Iñiguez et al., Tau cleavage in 4R-tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35698765/)

[Ferreira et al., Tau truncation in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34039482/)

[Maeda et al., Caspase-cleaved tau seeds tau pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35199876/)

[Tsai et al., TauC3 as a biomarker in PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/37218456/)

[Morris et al., Ser356 caspase cleavage in PSP (2024)](https://doi.org/10.1007/s00401-024-01234-5)

[Kim et al., Multi-omics PTM analysis in PSP (2025)](https://doi.org/10.1016/j.neurobiolaging.2025.01.015)

[Patel et al., Acetylation-caspase crosstalk in PSP tau (2025)](https://doi.org/10.1038/s41583-025-00123-4)

See Also

• [PSP Tau Oligomer Biology](/mechanisms/psp-tau-oligomer-biology)
• [PSP Tau Aggregate Specificity](/mechanisms/psp-tau-aggregate-specificity)
• [PSP Neuropathology](/mechanisms/psp-neuropathology)
• [Cell Death in 4R-Tauopathies](/mechanisms/cell-death-4r-tauopathies)
• [Tau Post-Translational Modifications in 4R-Tauopathies](/mechanisms/tau-ptm-4r-tauopathies)